{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:16Z","timestamp":1791489676582,"version":"4.3.4"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":257,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101449","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:53:53Z","timestamp":1789851233000},"page":"101449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oncolytic virotherapy at the tumor microenvironment\u2013CAR Therapy interface: Mechanisms, clinical translation, and future directions"],"prefix":"10.1016","volume":"49","author":[{"given":"Ali M","family":"Atoom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasur","family":"Rizaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Polatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pareshkumar N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.V.","family":"Jamuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmidhar","family":"Maharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Bainsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/86297","article-title":"A fresh look at tumor immunosurveillance and immunotherapy","volume":"2","author":"Smyth","year":"2001","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101449_bib0003","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2015.07.045","article-title":"PD-1 blockers","volume":"162","author":"Wolchok","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0006","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0007","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0008","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40259-019-00367-0","article-title":"Oncolytic viruses: priming time for cancer immunotherapy","volume":"33","author":"Russell","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.ctarc.2026.101449_bib0009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.omto.2020.01.001","article-title":"The PERK inhibitor GSK2606414 enhances reovirus infection in head and neck squamous cell carcinoma via an ATF4-dependent mechanism","volume":"16","author":"McLaughlin","year":"2020","journal-title":"Mol. Ther. Oncolytics."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0010","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/ijms21031106","article-title":"STAT3\/5 inhibitors suppress proliferation in bladder cancer and enhance oncolytic adenovirus therapy","volume":"21","author":"Hindupur","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"42","key":"10.1016\/j.ctarc.2026.101449_bib0011","doi-asserted-by":"crossref","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","article-title":"Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers","volume":"111","author":"Lin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0012","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2026.101449_bib0013","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trsl.2021.04.008","article-title":"Development of oncolytic viruses for cancer therapy","volume":"237","author":"Abd-Aziz","year":"2021","journal-title":"Transl. Res."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101449_bib0014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat, Rev, Drug Discov."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101449_bib0015","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/cdd.2013.84","article-title":"Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments","volume":"21","author":"Inoue","year":"2014","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ctarc.2026.101449_bib0018","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0019","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death. Dis."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends. Immunol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0022","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/icb.2013.58","article-title":"The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer?","volume":"91","author":"Escamilla-Tilch","year":"2013","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"471","key":"10.1016\/j.ctarc.2026.101449_bib0024","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau0417","article-title":"MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation","volume":"10","author":"Bommareddy","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0025","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0026","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41467-017-00324-x","article-title":"Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0027","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1022302","article-title":"Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy","volume":"4","author":"Qiao","year":"2015","journal-title":"Oncoimmunology"},{"issue":"25","key":"10.1016\/j.ctarc.2026.101449_bib0029","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0030","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005449","article-title":"The herpes simplex virus neurovirulence factor \u03b334. 5: revealing virus-host interactions","volume":"12","author":"Wilcox","year":"2016","journal-title":"PLoS. Pathog."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0032","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101449_bib0035","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0039","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of Talimogene Laherparepvec combined with Pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0041","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101449_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003119","article-title":"Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB\/II trial","volume":"9","author":"Monga","year":"2021","journal-title":"J. ImmunOther Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0203","first-page":"450","article-title":"Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial","volume":"29","author":"Soliman","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0033","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat, Rev, Drug Discov."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101449_bib0034","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2026.101449_bib0036","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","article-title":"1037O MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)","volume":"32","author":"Ribas","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0037","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00330-020-07249-y","article-title":"Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial","volume":"31","author":"Ahmed","year":"2021","journal-title":"Eur. Radiol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010662","article-title":"Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia\/Ib trial results and biomarker insights","volume":"13","author":"Wang","year":"2025","journal-title":"J. ImmunOther Cancer"},{"issue":"24","key":"10.1016\/j.ctarc.2026.101449_bib0040","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2217\/fon-2020-0246","article-title":"SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer","volume":"16","author":"Pascual","year":"2020","journal-title":"Future Oncol."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101449_bib0042","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101449_bib0043","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0044","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1128\/jvi.62.8.2970-2977.1988","article-title":"An ICP6:: lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis","volume":"62","author":"Goldstein","year":"1988","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0045","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/imt-2019-0033","article-title":"Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety","volume":"11","author":"Raman","year":"2019","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0047","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-20-3105","article-title":"A phase I trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer","volume":"27","author":"Soliman","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0048","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/35087061","article-title":"Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1","volume":"3","author":"Farassati","year":"2001","journal-title":"Nat. Cell Biol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101449_bib0049","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.gt.3302289","article-title":"HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival","volume":"11","author":"Harrow","year":"2004","journal-title":"Gene Ther."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101449_bib0050","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-16-2900","article-title":"Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients","volume":"23","author":"Streby","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0051","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s43018-024-00879-x","article-title":"Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)","volume":"6","author":"Ressler","year":"2025","journal-title":"Nat. Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0052","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11912-024-01611-9","article-title":"Talimogene laherparepvec (T-Vec) and emerging intralesional immunotherapies for metastatic melanoma: a review","volume":"26","author":"Kalsi","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0053","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Rivera-Orellana","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0054","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2017.230","article-title":"Development of gene therapeutics for head and neck cancer in China: from bench to bedside","volume":"29","author":"Guo","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40880-017-0227-2","article-title":"Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study","volume":"36","author":"He","year":"2017","journal-title":"Chin. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0056","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101449_bib0057","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4105","article-title":"Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI)","volume":"42","author":"Shen","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105746","article-title":"Small RNA sequence analysis of adenovirus VA RNA-derived MiRNAs reveals an unexpected serotype-specific difference in structure and abundance","volume":"9","author":"Kamel","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.ctarc.2026.101449_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152852","article-title":"A chimeric oncolytic adenovirus carried by macrophages for glioma immunotherapy","volume":"790","author":"Tang","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101449_bib0060","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/cancers17193180","article-title":"Oncolytic virus therapies in malignant gliomas: advances and clinical trials","volume":"17","author":"Yang","year":"2025","journal-title":"Cancers. (Basel)"},{"issue":"14","key":"10.1016\/j.ctarc.2026.101449_bib0061","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0062","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J. ImmunOther Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0063","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.958937","article-title":"Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization","volume":"3","author":"Ranki","year":"2014","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101449_bib0064","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1017702","article-title":"Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer","volume":"4","author":"Vassilev","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors-an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. ImmunOther Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101449_bib0066","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.4161\/21645515.2014.973323","article-title":"TroVax in colorectal cancer","volume":"10","author":"Rowe","year":"2014","journal-title":"Hum. Vaccin. ImmunOther"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0067","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2579","article-title":"Effect of modified vaccinia Ankara-5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: a randomized clinical trial","volume":"3","author":"Scurr","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101449_bib0068","first-page":"755","article-title":"Cancer vaccines: a brief overview","volume":"1403","author":"Thomas","year":"2016"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0069","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.euf.2018.08.016","article-title":"A randomized, double-blind, phase II trial of PSA-TRICOM (PROSTVAC) in patients with localized prostate cancer: the immunotherapy to prevent progression on active surveillance study","volume":"4","author":"Parsons","year":"2018","journal-title":"Eur. Urol. Focus."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0070","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00432-018-2762-x","article-title":"Progress in gene therapy using oncolytic vaccinia virus as vectors","volume":"144","author":"Yang","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7362","key":"10.1016\/j.ctarc.2026.101449_bib0071","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0072","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/mt.2014.194","article-title":"First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity","volume":"23","author":"Zeh","year":"2015","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0073","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2014.243","article-title":"Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients","volume":"23","author":"Cripe","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2026.101449_bib0074","series-title":"Gene Therapy of Solid Cancers: Methods and Protocols","first-page":"343","article-title":"A phase 2, open-label, randomized study of Pexa-Vec (JX-594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma","author":"Breitbach","year":"2015"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0075","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent advances of oncolytic virus in cancer therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum. Vaccin. ImmunOther"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101449_bib0076","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/vaccines12091010","article-title":"Dose considerations for vaccinia oncolytic virus based on retrospective reanalysis of early and late clinical trials","volume":"12","author":"Cyrelle Ornella","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"07","key":"10.1016\/j.ctarc.2026.101449_bib0077","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/CM9.0000000000003585","article-title":"Research progress and development potential of oncolytic vaccinia virus","volume":"138","author":"Zhang","year":"2025","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ctarc.2026.101449_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1594621","article-title":"Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy","volume":"15","author":"Zha","year":"2025","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101449_bib0079","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101449_bib0080","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0081","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1568009617666170222125035","article-title":"Clinical trials with oncolytic measles virus: current status and future prospects","volume":"18","author":"Msaouel","year":"2018","journal-title":"Curr. Cancer Drug Targets."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0082","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0083","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","article-title":"Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial","volume":"15","author":"Galanis","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0084","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0085","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2026.101449_bib0086","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/1078-0432.CCR-24-3721","article-title":"Measles oncolytic virus as an immunotherapy for recurrent\/refractory pediatric medulloblastoma and atypical teratoid\/rhabdoid tumor: results from PNOC005","volume":"31","author":"Yu","year":"2025","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.ctarc.2026.101449_bib0087","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/OTT.S518407","article-title":"Measles virus-based genetic modifications: progress in hematological malignancy treatment","volume":"18","author":"Lan","year":"2025","journal-title":"Onco Targets. Ther."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0088","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.mt.6300403","article-title":"A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas","volume":"16","author":"Forsyth","year":"2008","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0089","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"Kicielinski","year":"2014","journal-title":"Mol. Ther."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101449_bib0090","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","article-title":"A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer","volume":"14","author":"Vidal","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.ctarc.2026.101449_bib0091","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1158\/1078-0432.CCR-14-1404","article-title":"A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma","volume":"20","author":"Sborov","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0092","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/mt.2012.146","article-title":"Phase II trial of intravenous administration of Reolysin\u00ae(Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma","volume":"20","author":"Galanis","year":"2012","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0093","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1038\/s41467-024-53347-6","article-title":"Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer","volume":"15","author":"Lee","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101449_bib0094","article-title":"Reovirus therapy: oral administration can change the dynamics of the gut microbiota to boost antitumor immunity in colon cancer","volume":"2","author":"Balachandran","year":"2025","journal-title":"Cancer Pathog. Ther."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat, Rev, Drug Discov."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101449_bib0096","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/biomedicines8070204","article-title":"Bi-and tri-specific T cell engager-armed oncolytic viruses: next-generation cancer immunotherapy","volume":"8","author":"Guo","year":"2020","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0097","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101449_bib0098","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-17-2651","article-title":"Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors","volume":"24","author":"Speck","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0099","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001292","article-title":"Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy","volume":"9","author":"Khalique","year":"2021","journal-title":"J. ImmunOther Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jnci\/83.2.91","article-title":"Tumor suppressor genes: new prospects for cancer research","volume":"83","author":"Hollingsworth","year":"1991","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0101","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1038\/s41467-018-07344-1","article-title":"PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance","volume":"9","author":"Russell","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101449_bib0102","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2017.03.002","article-title":"Combining oncolytic virotherapy with p53 tumor suppressor gene therapy","volume":"5","author":"Bressy","year":"2017","journal-title":"Mol. Ther. Oncolytics."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101449_bib0103","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.molonc.2011.10.001","article-title":"Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer","volume":"5","author":"Liu","year":"2011","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101449_bib0104","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/1535-7163.MCT-07-2429","article-title":"A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers","volume":"7","author":"Wang","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101449_bib0105","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/sj.cgt.7700936","article-title":"Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2-and E1b-55kD-mediated degradation of p53","volume":"13","author":"Sauthoff","year":"2006","journal-title":"Cancer Gene Ther."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101449_bib0106","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.3390\/pharmaceutics14091811","article-title":"Strategies for advanced oncolytic virotherapy: current technology innovations and clinical approaches","volume":"14","author":"Ji","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0107","first-page":"353.e1","article-title":"Antitumor effect of a dual cancer-specific oncolytic adenovirus on prostate cancer PC-3 cells","volume":"37","author":"Cui","year":"2019","journal-title":"Urol. Oncol.: Semin. Orig. Investig."},{"key":"10.1016\/j.ctarc.2026.101449_bib0108","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2017.02.042","article-title":"Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy","volume":"802","author":"Wu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0109","article-title":"Recombinant vaccinia viruses coding transgenes of apoptosis-inducing proteins enhance apoptosis but not immunogenicity of infected tumor cells","volume":"2017","author":"Koval","year":"2017","journal-title":"BioMed. Res. Int."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101449_bib0110","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0111","doi-asserted-by":"crossref","first-page":"e01677","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ctarc.2026.101449_bib0113","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2021.06.005","article-title":"Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody","volume":"518","author":"Tian","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ctarc.2026.101449_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/cr.2009.126","article-title":"VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis","volume":"20","author":"Xiao","year":"2010","journal-title":"Cell Res."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101449_bib0116","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/gt.2008.82","article-title":"Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus","volume":"15","author":"Foloppe","year":"2008","journal-title":"Gene Ther."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0117","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/sj.gt.3300671","article-title":"Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450","volume":"5","author":"L\u00f6hr","year":"1998","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0118","first-page":"229","article-title":"Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene","volume":"4","author":"Green","year":"1997","journal-title":"Cancer Gene Ther."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101449_bib0119","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/ijms18061231","article-title":"Gene therapy for pancreatic cancer: specificity, issues and hopes","volume":"18","author":"Rouanet","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101449_bib0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","article-title":"Lighting a fire in the tumor microenvironment using oncolytic immunotherapy","volume":"31","author":"Achard","year":"2018","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0121","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trecan.2016.11.009","article-title":"Targeted therapy and immunosuppression in the tumor microenvironment","volume":"3","author":"Allegrezza","year":"2017","journal-title":"Trends. Cancer"},{"key":"10.1016\/j.ctarc.2026.101449_bib0122","series-title":"Oncolytic Viruses: Methods and Protocols","first-page":"191","article-title":"Detection of tumor antigen-specific T-cell responses after oncolytic vaccination","author":"Pol","year":"2019"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0123","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/jir.2017.0060","article-title":"Investigation of the cellular immune response to recombinant fragments of filamentous hemagglutinin and pertactin of Bordetella pertussis in BALB\/c mice","volume":"38","author":"Bakhshaei","year":"2018","journal-title":"J. Interferon Cytokine Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0124","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/jmv.25677","article-title":"Chimeric oncolytic Ad5\/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor","volume":"92","author":"Kuryk","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ctarc.2026.101449_bib0125","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jcis.2018.12.032","article-title":"Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer","volume":"538","author":"Wang","year":"2019","journal-title":"J. Colloid. Interface Sci."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0126","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41417-020-0176-9","article-title":"Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and\/or CD40","volume":"27","author":"Wenthe","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"15\u201316","key":"10.1016\/j.ctarc.2026.101449_bib0127","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/hum.2020.024","article-title":"Oncolytic adenovirus expressing ST13 increases antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic ductal adenocarcinoma","volume":"31","author":"Zhang","year":"2020","journal-title":"Hum. Gene Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0128","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/cells9040798","article-title":"TNFa and IL2 encoding oncolytic adenovirus activates pathogen and danger-associated immunological signaling","volume":"9","author":"Heini\u00f6","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0129","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jtho.2019.12.128","article-title":"Frequent homozygous deletions of type I interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus","volume":"15","author":"Delaunay","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0130","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg. Oncol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101449_bib0131","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1158\/1078-0432.CCR-17-0681","article-title":"Local delivery of OncoVEXmGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade","volume":"23","author":"Moesta","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7385","key":"10.1016\/j.ctarc.2026.101449_bib0132","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature10803","article-title":"Expression of tumour-specific antigens underlies cancer immunoediting","volume":"482","author":"DuPage","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0133","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/0008-5472.CAN-07-3095","article-title":"Epitope landscape in breast and colorectal cancer","volume":"68","author":"Segal","year":"2008","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0134","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0135","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101449_bib0136","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1111\/jcmm.15089","article-title":"Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0137","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.1701021","article-title":"Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies","volume":"200","author":"van Vloten","year":"2018","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0138","doi-asserted-by":"crossref","first-page":"9080","DOI":"10.1002\/jcp.29769","article-title":"Immune checkpoints in hematologic malignancies: what made the immune cells and clinicians exhausted!","volume":"235","author":"Hajifathali","year":"2020","journal-title":"J. Cell Physiol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101449_bib0139","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0140","article-title":"Hypoxic Wharton\u2019s jelly stem cell conditioned medium induces immunogenic cell death in lymphoma cells","volume":"2020","author":"Lin","year":"2020","journal-title":"Stem Cells Int."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101449_bib0141","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-020-02495-x","article-title":"Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro","volume":"69","author":"Burke","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101449_bib0142","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aal1713","article-title":"Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells","volume":"2","author":"Dai","year":"2017","journal-title":"Sci. Immunol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0143","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0144","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ctarc.2026.101449_bib0145","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3389\/fimmu.2020.01849","article-title":"Arenavirus induced CCL5 expression causes NK cell-mediated melanoma regression","volume":"11","author":"Bhat","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0146","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI98047","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ctarc.2026.101449_bib0147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.765036","article-title":"The expression of CD28 and its synergism on the immune response of flounder (Paralichthys olivaceus) to thymus-dependent antigen","volume":"12","author":"Xing","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0148","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.canlet.2010.01.011","article-title":"Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses","volume":"293","author":"Youlin","year":"2010","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101449_bib0149","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat, Rev, Drug Discov."},{"issue":"Suppl 2","key":"10.1016\/j.ctarc.2026.101449_bib0150","article-title":"955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)","volume":"9","author":"Li","year":"2021","journal-title":"J. ImmunOther Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101449_bib0151","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2600","article-title":"Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian cancer (OC) or metastatic colorectal cancer (CRC): Phase 2 results","volume":"40","author":"Zamarin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101449_bib0152","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"Chaurasiya","year":"2018","journal-title":"Curr. Opin. Immunol."},{"issue":"138","key":"10.1016\/j.ctarc.2026.101449_bib0153","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003578","article-title":"Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients","volume":"4","author":"Adair","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0154","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.3390\/v7122921","article-title":"Stem cell-based cell carrier for targeted oncolytic virotherapy: translational opportunity and open questions","volume":"7","author":"Kim","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.ctarc.2026.101449_bib0155","first-page":"47","article-title":"Cell carriers for oncolytic viruses: current challenges and future directions","volume":"2","author":"Roy","year":"2013","journal-title":"Oncolytic. Virther."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0156","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ymthe.2021.02.004","article-title":"Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity","volume":"29","author":"McKenna","year":"2021","journal-title":"Mol. Ther."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101449_bib0157","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1158\/0008-5472.CAN-18-3900","article-title":"Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma","volume":"79","author":"Yoon","year":"2019","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101449_bib0158","doi-asserted-by":"crossref","first-page":"19352","DOI":"10.1002\/jcp.28657","article-title":"NK cells: an attractive candidate for cancer therapy","volume":"234","author":"Valipour","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0159","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0160","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0161","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0162","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103470","article-title":"An inter-supplementary biohybrid system based on natural killer cells for the combinational immunotherapy and virotherapy of cancer","volume":"9","author":"Ding","year":"2022","journal-title":"Adv. Sci."},{"issue":"640","key":"10.1016\/j.ctarc.2026.101449_bib0163","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0164","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41467-018-03233-9","article-title":"Optically-controlled bacterial metabolite for cancer therapy","volume":"9","author":"Zheng","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0165","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1038\/s41467-021-26956-8","article-title":"Aptamer-assisted tumor localization of bacteria for enhanced biotherapy","volume":"12","author":"Geng","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0166","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1021\/acs.nanolett.2c00699","article-title":"Boarding oncolytic viruses onto tumor-homing bacterium-vessels for augmented cancer immunotherapy","volume":"22","author":"Sun","year":"2022","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0167","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jtho.2019.09.083","volume":"15","author":"Schenk","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2138","key":"10.1016\/j.ctarc.2026.101449_bib0168","doi-asserted-by":"crossref","DOI":"10.1098\/rsta.2018.0268","article-title":"Re-designing materials for biomedical applications: from biomimicry to nature-inspired chemical engineering","volume":"377","author":"Perera","year":"2019","journal-title":"Philos. Trans. R. Soc. A"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0169","article-title":"Emerging delivery strategy for oncolytic virotherapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101449_bib0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma","volume":"34","author":"Abramson","year":"2020","journal-title":"Transfus. Med. Rev."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0171","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1097\/JS9.0000000000003988","article-title":"Chimeric antigen receptor T-cell therapy in patients with lymphoma: a machine learning-driven decadal informatics network analysis","volume":"112","author":"Guo","year":"2026","journal-title":"Int. J. Surg."},{"issue":"26","key":"10.1016\/j.ctarc.2026.101449_bib0172","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101449_bib0173","article-title":"Long-term clinical outcomes of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory ALL","volume":"29","author":"Grupp","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101449_bib0174","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2023.6.JNS23243","article-title":"Oncolytic viral therapy: a review and promising future directions","volume":"140","author":"Reddy","year":"2024","journal-title":"J. Neurosurg."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0175","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","article-title":"An oncolytic virus-T cell chimera for cancer immunotherapy","volume":"42","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101449_bib0176","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0177","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101449_bib0178","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010016","article-title":"First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments","volume":"12","author":"Naing","year":"2024","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2026.101449_bib0179","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response","volume":"15","author":"Webb","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101449_bib0180","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41467-025-56482-w","article-title":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial","volume":"16","author":"Block","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0181","article-title":"Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma","volume":"6","author":"Monberg","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"33","key":"10.1016\/j.ctarc.2026.101449_bib0182","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0183","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013692","article-title":"Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling","volume":"14","author":"Roulstone","year":"2026","journal-title":"J. ImmunOther Cancer"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101449_bib0184","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1158\/1078-0432.CCR-24-2701","article-title":"A phase II randomized study of paclitaxel alone or combined with pelareorep with or without avelumab in metastatic hormone receptor-positive breast cancer: the BRACELET-01\/PrE0113 study","volume":"31","author":"Clark","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101449_bib0185","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1038\/s41467-025-58407-z","article-title":"Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101449_bib0186","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40364-025-00726-w","article-title":"SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis","volume":"13","author":"Chen","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ctarc.2026.101449_bib0187","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455163","article-title":"Oncolytic virus and CAR-T cell therapy in solid tumors","volume":"15","author":"Ponterio","year":"2024","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101449_bib0188","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011127","article-title":"Oncolytic viruses as reliable adjuvants in CAR-T cell therapy for solid tumors","volume":"25","author":"Stilpeanu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101449_bib0189","article-title":"Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification","volume":"32","author":"Tonne","year":"2024","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.ctarc.2026.101449_bib0190","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1038\/s41467-026-71021-x","article-title":"Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs","volume":"17","author":"Li","year":"2026","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101449_bib0191","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.ymthe.2022.06.010","article-title":"An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ","volume":"30","author":"Ye","year":"2022","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0192","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow TransPlant"},{"key":"10.1016\/j.ctarc.2026.101449_bib0193","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ebiom.2019.07.066","article-title":"Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma","volume":"47","author":"Andtbacka","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctarc.2026.101449_bib0194","series-title":"IMLYGIC (talimogene laherparepvec) Prescribing Information","year":"2015"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101449_bib0195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade6790","article-title":"Ultralow-dose binary oncolytic\/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies","volume":"9","author":"Wang","year":"2023","journal-title":"Sci. Adv."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101449_bib0196","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2679","article-title":"Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA)","volume":"42","author":"Makawita","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101449_bib0197","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.3934\/mbe.2022205","article-title":"A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept","volume":"19","author":"Mahasa","year":"2022","journal-title":"Math. Biosci. Eng."},{"key":"10.1016\/j.ctarc.2026.101449_bib0198","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2025.109531","article-title":"CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma","volume":"389","author":"Conte","year":"2025","journal-title":"Math. Biosci."},{"key":"10.1016\/j.ctarc.2026.101449_bib0199","doi-asserted-by":"crossref","DOI":"10.1016\/j.chaos.2025.116418","article-title":"Threshold dynamics of a stochastic tumor-immune model combined oncolytic virus and chimeric antigen receptor T cell therapies","volume":"197","author":"Zhou","year":"2025","journal-title":"Chaos. Solitons. Fractals."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101449_bib0200","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","article-title":"Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials","volume":"22","author":"Yuan","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101449_bib0201","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/09622802241236936","article-title":"BOIN-ETC: a bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations","volume":"33","author":"Kakizume","year":"2024","journal-title":"Stat. Methods Med. Res."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101449_bib0202","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","article-title":"Safety, efficacy, and biological data of T-cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial","volume":"30","author":"Pakola","year":"2024","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600359X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600359X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:46:38Z","timestamp":1791488798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422600359X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":202,"alternative-id":["S246829422600359X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101449","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic virotherapy at the tumor microenvironment\u2013CAR Therapy interface: Mechanisms, clinical translation, and future directions","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101449"}}